From: Role of maspin in cancer
Authors | Year | N. patients | Maspin expression | Clinical pathological features/prognosis |
---|---|---|---|---|
Umekita et al. | 2003 | 92 (invasive breast cancer) | 18.5% positive maspin | Positive maspin in invasive breast cancer and DCIS = large tumor size, presence of comedo-necrosis and high grade |
145 (Ductal Carcinoma In Situ) | 9.6%positive maspin | |||
27 (atypical hyperplasia) | 3.7% positive maspin | |||
94 (usual hyperplasia) | 0%positive maspin | |||
Kim et al. | 2003 | 192 (stage I-II breast cancer) | 34.4% positive maspin | Positive maspin in all type of invasive breast cancer = high grade |
36.4% positive maspin in invasive ductal carcinoma | ||||
7.1% positive maspin in invasive lobular carcinoma) | ||||
Mohsin at al. | 2003 | 1068 (breast cancer) | 35% positive cytoplasm | Positive cytoplasmic maspin = negative ER and PgR, high Mib, aneuploidy |
96% positive nucleus | Positive nuclear maspin = positive ER and PgR | |||
Umekita et al. | 2002 | 168 (breast cancer) | 27.4% positive maspin | Positive maspin = 17.4% Large tumor size, 43.4% high grade, 65.2% negative ER and PgR, 43.4% positive p53 shorter PFS and OS |
72.6% negative maspin | Negative maspin = 9% large tumor size, 19.6% high grade 35.2% negative ER and PgR 20,5% positive p53, better PFS and OS | |||
Umekita et al. | 2011 | 135 (triple negative breast cancer) | 85.9% positive maspin | Positive maspin = 43.1% age ≤ 50 years, 80.2% high grade |
14.1% negative maspin | Negative maspin = 5.2% age ≤ 50 years, 42.1% high grade | |||
Lee et al. | 2006 | 80 (breast cancer) | 31.3% positive maspin | Positive maspin = 24% large tumor size, 52% high grade, 80% negative PgR, Short PFS and OS |
68.7% negative maspin | Negative maspin = 7.2% large tumor size, 21.8% high grade, 41.8% negative PgR, better PFS and OS | |||
Stark et al. | 2012 | 16 (metastatic breast cancer) | 30% positive maspin in primary tumor | |
13% positive maspin in brain metastasis | ||||
Maass et al. | 2001 | 45 (breast cancer) | 64% positive maspin | 17.7% of patients develop metastasis = 75% negative maspin |
36% negative maspin |